KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Ultrahypofractionated linac-based radiotherapy of primary prostate cancer - early results of an Austrian nationwide registry study.

Natalee Annon-Eberharter, Johannes Berchtold, Angela Ginestet, Georg Gruber, Lukas Kocik, Oxana Komina, Tanja Langsenlehner, Elisabeth Nechvile, Christoph Resl, Falk Röder, Samuel M Vorbach, Ludmila Zahlbruckner, Frank Wolf

Clin Transl Radiat Oncol 61 101242

PMID42621857
PMCIDPMC13487599
DOI10.1016/j.ctro.2026.101242
发表日期2026-08-20
入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要

摘要

BACKGROUND AND PURPOSE: Ultrahypofractionated radiotherapy (UHFX) has emerged as an attractive alternative to normo- and moderately hypofractionated regimens for localized prostate cancer. However, its broader adoption remains limited by technical challenges and concerns regarding genitourinary toxicity. We established a nationwide Austrian registry of low and intermediate risk localized prostate cancer patients treated with linac-based stereotactic body radiation therapy (SBRT) to provide real-world data about UHFX treatment conventions, toxicity, oncologic outcomes, and patient-reported quality of life (QoL). METHODS: This is a multicenter, registry-based prospective study. Eligibility was restricted to patients with low- and intermediate-risk prostate cancer. Patient characteristics, toxicity (CTCAE v5.1), urinary function (IPSS), and QoL (EPIC-26) were prospectively reported in a web-based database. RESULTS: Between September 2022 and April 2026, 191 patients were enrolled, of whom 169 were included in the final analysis. Median follow-up was 14 months (IQR 7-24). NCCN risk distribution consisted of 23.7% low-risk, 48.5% favorable intermediate-risk, and 27.8% unfavorable intermediate-risk disease. All patients received 40 Gy in five fractions. Treatment was delivered on alternating weekdays in 61.5% and on consecutive weekdays in 38.5% of patients. Median PSA declined from 7.74 ng/mL at baseline to 0.63 ng/mL at 12 months. No biochemical recurrence was observed during the first year of follow-up. Grade 1-2 genitourinary toxicity peaked at treatment completion and declined thereafter, while grade ≥ 3 toxicity remained uncommon (<1%). Gastrointestinal toxicity remained low throughout follow-up, with no grade ≥ 3 gastrointestinal toxicity observed. CONCLUSION: In this nationwide real-world cohort, UHFX delivered in five fractions was well tolerated and showed favorable early oncological outcomes with low rates of severe toxicity across academic and non-academic institutions, consistent with results from randomized phase III trials.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。